General Information of Drug (ID: DMNZAVE)

Drug Name
1h-Benoximidazole-2-Carboxylic Acid Drug Info
Synonyms
1H-Benzimidazole-2-carboxylic acid; 2849-93-6; 2-Benzimidazolecarboxylic acid; 1H-benzo[d]imidazole-2-carboxylic acid; Benzimidazole-2-carboxylic acid; 1H-Benzoimidazole-2-carboxylic acid; 1H-1,3-benzodiazole-2-carboxylic acid; Benzoimidazole-2-carboxylic acid; benzimidazole-2-yl-carboxylic acid; 1H-BENOXIMIDAZOLE-2-CARBOXYLIC ACID; 1h-1,3-benzimidazole-2-carboxylic acid; RHXSYTACTOMVLJ-UHFFFAOYSA-N; PubChem8062; AC1L5PLZ; benzimidazolecarboxylic acid; AC1Q1HJ4; benzimidazole carboxylic acid; 2-Carboxy-1H-benzimidazole
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
233240
ChEBI ID
CHEBI:46117
CAS Number
CAS 2849-93-6
TTD Drug ID
DMNZAVE

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug(s) Targeting Cathepsin D (CTSD)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID10498202C1 DMXE0F2 Multiple sclerosis 8A40 Clinical trial [2]
CI-992 DMBHYIJ Hypertension BA00-BA04 Terminated [3]
Alpha-D-Mannose DMF5DLW Discovery agent N.A. Investigative [1]
Grassystatin a DM1PWX2 Discovery agent N.A. Investigative [4]
PMID8410973C3 DM6J5KY Discovery agent N.A. Investigative [5]
KNI-10006 DMMISH6 Discovery agent N.A. Investigative [6]
GRL-7234 DMR93MK Discovery agent N.A. Investigative [7]
S-Methylcysteine DMAMRKS Discovery agent N.A. Investigative [1]
Carbocyclic Peptidomimetic DM87SOX Discovery agent N.A. Investigative [8]
N-Aminoethylmorpholine DMWXBYC Discovery agent N.A. Investigative [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cathepsin D (CTSD) TTPT2QI CATD_HUMAN Inhibitor [1]

References

1 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
2 Synthesis and structure activity relationships of novel small molecule cathepsin D inhibitors. Bioorg Med Chem Lett. 1999 Sep 6;9(17):2531-6.
3 Structure-activity relationships of a series of 2-amino-4-thiazole-containing renin inhibitors. J Med Chem. 1992 Jul 10;35(14):2562-72.
4 Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation. J Med Chem. 2009 Sep 24;52(18):5732-47.
5 Specificity in the binding of inhibitors to the active site of human/primate aspartic proteinases: analysis of P2-P1-P1'-P2' variation. J Med Chem. 1993 Sep 3;36(18):2614-20.
6 alpha-Substituted norstatines as the transition-state mimic in inhibitors of multiple digestive vacuole malaria aspartic proteases. Bioorg Med Chem. 2009 Aug 15;17(16):5933-49.
7 Design, synthesis, and X-ray structure of potent memapsin 2 (beta-secretase) inhibitors with isophthalamide derivatives as the P2-P3-ligands. J Med Chem. 2007 May 17;50(10):2399-407.
8 Structure-based design, synthesis, and memapsin 2 (BACE) inhibitory activity of carbocyclic and heterocyclic peptidomimetics. J Med Chem. 2005 Aug 11;48(16):5175-90.